- Home
- OCUL
as of 03-24-2026 3:54pm EST
$8.12
+$0.02
+0.19%
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 1.9B | IPO Year: | 2014 |
| Target Price: | $22.90 | AVG Volume (30 days): | 5.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.42 | EPS Growth: | -16.39 |
| 52 Week Low/High: | $6.23 - $16.44 | Next Earning Date: | 05-04-2026 |
| Revenue: | $1,990,000 | Revenue Growth: | 3.48% |
| Revenue Growth (this year): | 9.35% | Revenue Growth (next year): | 92.88% |
| P/E Ratio: | -5.75 | Index: | N/A |
| Free Cash Flow: | -216893000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Ocular Therapeutix Inc. (OCUL)
Nayak Sanjay
Sell
Chief Strategy Officer
OCUL Feb 23, 2026
Avg Cost/Share
$8.28
Shares
1,759
Total Value
$14,564.52
Owned After
330,653
SEC Form 4
Dugel Pravin
Sell
See Remarks
OCUL Feb 23, 2026
Avg Cost/Share
$8.28
Shares
20,056
Total Value
$166,063.68
Owned After
3,013,022
SEC Form 4
Kaiser Peter
Sell
Chief Development Officer
OCUL Feb 23, 2026
Avg Cost/Share
$8.28
Shares
2,810
Total Value
$23,266.80
Owned After
269,108
SEC Form 4
Heier Jeffrey S.
Sell
Chief Scientific Officer
OCUL Feb 23, 2026
Avg Cost/Share
$8.28
Shares
3,057
Total Value
$25,311.96
Owned After
323,368
SEC Form 4
LINDSTROM RICHARD L MD
Buy
Director
OCUL Feb 20, 2026
Avg Cost/Share
$7.66
Shares
60,229
Total Value
$461,354.14
Owned After
246,933
SEC Form 4
Waheed Nadia
Sell
Chief Medical Officer
OCUL Feb 20, 2026
Avg Cost/Share
$7.74
Shares
3,510
Total Value
$27,167.40
Owned After
314,907
SEC Form 4
Nayak Sanjay
Sell
Chief Strategy Officer
OCUL Feb 12, 2026
Avg Cost/Share
$9.04
Shares
10,348
Total Value
$93,545.92
Owned After
330,653
SEC Form 4
Notman Donald
Sell
Chief Operating Officer
OCUL Feb 12, 2026
Avg Cost/Share
$9.04
Shares
11,446
Total Value
$103,471.84
Owned After
366,356
SEC Form 4
Dugel Pravin
Sell
See Remarks
OCUL Feb 12, 2026
Avg Cost/Share
$9.04
Shares
124,882
Total Value
$1,128,933.28
Owned After
3,013,022
SEC Form 4
Waheed Nadia
Sell
Chief Medical Officer
OCUL Feb 12, 2026
Avg Cost/Share
$9.04
Shares
7,863
Total Value
$71,081.52
Owned After
314,907
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Nayak Sanjay | OCUL | Chief Strategy Officer | Feb 23, 2026 | Sell | $8.28 | 1,759 | $14,564.52 | 330,653 | |
| Dugel Pravin | OCUL | See Remarks | Feb 23, 2026 | Sell | $8.28 | 20,056 | $166,063.68 | 3,013,022 | |
| Kaiser Peter | OCUL | Chief Development Officer | Feb 23, 2026 | Sell | $8.28 | 2,810 | $23,266.80 | 269,108 | |
| Heier Jeffrey S. | OCUL | Chief Scientific Officer | Feb 23, 2026 | Sell | $8.28 | 3,057 | $25,311.96 | 323,368 | |
| LINDSTROM RICHARD L MD | OCUL | Director | Feb 20, 2026 | Buy | $7.66 | 60,229 | $461,354.14 | 246,933 | |
| Waheed Nadia | OCUL | Chief Medical Officer | Feb 20, 2026 | Sell | $7.74 | 3,510 | $27,167.40 | 314,907 | |
| Nayak Sanjay | OCUL | Chief Strategy Officer | Feb 12, 2026 | Sell | $9.04 | 10,348 | $93,545.92 | 330,653 | |
| Notman Donald | OCUL | Chief Operating Officer | Feb 12, 2026 | Sell | $9.04 | 11,446 | $103,471.84 | 366,356 | |
| Dugel Pravin | OCUL | See Remarks | Feb 12, 2026 | Sell | $9.04 | 124,882 | $1,128,933.28 | 3,013,022 | |
| Waheed Nadia | OCUL | Chief Medical Officer | Feb 12, 2026 | Sell | $9.04 | 7,863 | $71,081.52 | 314,907 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 5, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 5, 2026 · 100% conf.
AI Prediction BUY
1D
+1.83%
$9.07
Act: +2.81%
5D
+8.68%
$9.68
Act: +1.68%
20D
+6.49%
$9.49
Act: +14.87%
Price: $8.91 Prob +5D: 100% AUC: 1.000
0001104659-26-010633
false 0001393434
0001393434
2026-02-05 2026-02-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 5, 2026
OCULAR
THERAPEUTIX, INC.
(Exact Name of Company as Specified in Charter)
Delaware
001-36554
20-5560161
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
15 Crosby Drive
Bedford,
MA 01730
(Address of Principal Executive Offices) (Zip Code)
Company’s telephone number, including area code: (781) 357-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, $0.0001 par value per share
OCUL
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On February 5, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
99.1 Press Release of Ocular Therapeutix, Inc., dated February 5, 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OCULAR THERAPEUTIX, INC.
Date: February 5, 2026 By: /s/ Jason S. Robins
Jason S. Robins
Interim Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 4, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 4, 2025
0001104659-25-105914
false 0001393434
0001393434
2025-11-04 2025-11-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2025
OCULAR
THERAPEUTIX, INC.
(Exact Name of Company as Specified in Charter)
Delaware
001-36554
20-5560161
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
15 Crosby Drive
Bedford,
MA 01730
(Address of Principal Executive Offices) (Zip Code)
Company’s telephone number, including area code: (781) 357-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, $0.0001 par value per share
OCUL
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On November 4, 2025, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
99.1 Press Release of Ocular Therapeutix, Inc., dated November 4, 2025
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OCULAR THERAPEUTIX, INC.
Date: November 4, 2025 By: /s/ Donald Notman
Donald Notman
Chief Financial Officer and Chief Operating Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 5, 2025
0001104659-25-073909
false 0001393434
0001393434
2025-08-05 2025-08-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 5, 2025
OCULAR
THERAPEUTIX, INC.
(Exact Name of Company as Specified in Charter)
Delaware
001-36554
20-5560161
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
15 Crosby Drive
Bedford,
MA 01730
(Address of Principal Executive Offices) (Zip Code)
Company’s telephone number, including area code: (781) 357-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, $0.0001 par value per share
OCUL
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2025, Ocular Therapeutix, Inc. announced its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
99.1 Press Release of Ocular Therapeutix, Inc., dated August 5, 2025
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OCULAR THERAPEUTIX, INC.
Date: August 5, 2025 By: /s/ Donald Notman
Donald Notman
Chief Operating Officer and Chief Financial Officer
Latest Ocular Therapeutix Inc. News
OCUL Breaking Stock News: Dive into OCUL Ticker-Specific Updates for Smart Investing
Reuters
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
📉
AI Sentiment
Negative
3/10
Motley Fool
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
📉
AI Sentiment
Negative
2/10
Simply Wall St.
Is It Time To Reassess Ocular Therapeutix (OCUL) After Its Recent Share Price Slide
➖
AI Sentiment
Neutral
4/10
Compare OCUL vs Leading Stocks
See how OCUL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "OCUL Ocular Therapeutix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.